Mean platelet volume and coronary artery disease. (July 2019)

• Record Type: Journal Article
• Authors: Pafili, Kalliopi; Penlioglou, Theano; Mikhailidis, Dimitri P.; Papanas, Nikolaos
• Is Part Of: Current opinion in cardiology. Volume 34:Number 4(2019:Jul.)
• Publication Date: 2019-07
• Subjects: coronary artery disease -- diabetes mellitus -- mean platelet volume -- platelets; Cardiology -- Periodicals; Cardiology -- Periodicals; Heart Diseases -- Periodicals; Cardiology; Periodicals; 616.12
• DOI: 10.1097/HCO.0000000000000624
• Languages: English
• ISSNs: 0268-4705

Abstract

Abstract : Purpose of review: To critically review the literature describing links between mean platelet volume (MPV) and cardiovascular disease (CVD). We will focus on coronary artery disease (CAD). The MPV is measured routinely as part of a routine blood count. Recent findings: There is accumulating evidence showing that the MPV may predict CVD, as well as outcomes in patients with CAD. There is also evidence linking MPV and comorbidities (e.g. diabetes mellitus and impaired glycaemic control) that are expected in patients with CAD. The effect on MPV of drugs commonly used to treat CAD has not been clarified, but there is some evidence that they may exert a beneficial effect on the MPV. More specifically, the MPV may predict the effect of antiplatelet drugs (e.g. clopidogrel). There is also evidence relating MPV to stroke, atrial fibrillation, coronary artery ectasia and periprocedural outcomes after percutaneous coronary intervention (PCI). Summary: Measuring the MPV may prove useful in CVD risk assessment in patients with established CAD or at risk of developing CAD. Overall, there is evidence pointing to the role of MPV as a contributor rather than simple marker of CVD.